In tablet manufacturing, direct compression of ephedrine hydrochloride veterinary grade API begins with delumping through a 0.5 mm conical sieve and conditioned dry blending at 40–50% RH. Batch-to-batch particle size variability at D90 above 150 µm has been observed on production-scale bin blenders to drive assay RSD above 3.0% within a 10-minute cycle, so sieve-cut API is required when content uniformity is critical. The dry preblend is charged to a 600–1200 L diffusion blender with microcrystalline cellulose 30–45% w/w, spray-dried lactose monohydrate 25–40% w/w, croscarmellose sodium 2–4% w/w, and colloidal silicon dioxide 0.2–0.5% w/w; magnesium stearate 0.5–1.0% w/w is added for the final 3–5 minutes only because lubricant over-blending reduces tablet hardness and slows dissolution. Compression is performed on a rotary tablet press equipped with 8 mm round concave tooling, pre-compression force 2–5 kN, main compression force 6–15 kN, target hardness 4–8 kp, and friability NMT 1.0% after 100 revolutions per USP <1216>. Disintegration is tested per USP <701>, dissolution per USP <711> in 0.1 N hydrochloric acid or water at 37±0.5°C, and content uniformity per USP <905> with acceptance value ≤15.0. Wet granulation using 2–4% w/w povidone binder solution in a high-shear granulator is applied only when direct compression cannot meet blend uniformity; the wet mass is dried to loss on drying 1.0–2.0% w/w with inlet air not exceeding 60°C to limit oxidative degradation.

What Limits Uniform Drug Content in Low-Dose Ephedrine Capsule Blends?

For low-dose hard gelatin capsule filling, the limiting variable is not chemical incompatibility but dry blend segregation during dosage metering. Because direct addition of ephedrine sulfate at ≤5 mg per capsule to fill excipient yields assay standard deviations above 5.0% on dosator-type filling equipment, a staged geometric pre-blend is required before final blending. The API is first triturated with lactose monohydrate at a 1:10 ratio through a 0.3 mm screen, then diluted sequentially to 1:100 before charging a V-blender or double-cone blender. Final blend is prepared with pregelatinized starch 10–25% w/w as disintegrant, microcrystalline cellulose 10–30% w/w as compressible filler, and sodium lauryl sulfate 0.1–0.3% w/w when wet granulation is not used; magnesium stearate 0.5% w/w is added last with blend time not exceeding 5 minutes. Capsules are filled on a tamping pin machine to a target fill weight of 180–220 mg in size 3 hard gelatin or HPMC shells; empty shells are conditioned at 45–55% RH to prevent brittleness. Content uniformity is assessed by USP <905> with acceptance value ≤15.0; blend uniformity testing under 21 CFR 211.110 requires RSD ≤5.0% across 10 sampling locations. Dissolution testing per USP <711> uses 0.1 N hydrochloric acid or purified water at 37±0.5°C, with sampling at 15, 30, and 45 minutes where compendial tolerances apply. Processing above 60% RH is avoided because ephedrine hydrochloride may absorb surface moisture and reduce flowability; such conditions require preconditioning of the encapsulating suite and silica gel desiccant canisters in packaging.

Injectable Solution Sterilization Is pH-Dependent in Ephedrine Hydrochloride Veterinary Parenterals

After pH adjustment to 4.0–5.5 with citrate buffer, terminal steam sterilisation of ephedrine hydrochloride parenterals proceeds by filtration through 0.22 µm PES or PVDF membranes followed by autoclaving at 121°C for 15 minutes with a minimum F₀ of 8.0 minutes. Tonicity is adjusted with sodium chloride to 285–310 mOsm/kg; target ephedrine hydrochloride concentration is normally 50 mg/mL where compendial monograph alignment exists. The filled solution is held in Type I borosilicate glass vials with nitrogen overlay if oxidative degradation studies show headspace oxygen sensitivity; solution pH above 6.0 is avoided because free base precipitation and alkaline hydrolysis increase sharply. Multi-dose containers require antimicrobial preservation; benzyl alcohol 1.5% v/v is effective but is not acceptable in feline parenteral formulations because of documented neurological toxicity, so methylparaben 0.18% w/v with propylparaben 0.02% w/v is substituted for those species. Post-sterilisation particulate matter is tested per USP <788> small-volume limits of ≤6000 particles per container at ≥10 µm and ≤600 particles per container at ≥25 µm; sterility testing follows USP <71> with 14-day incubation. Incompatibility with sodium bicarbonate, thiopental, and strong oxidising agents is documented; admixture port precipitates may form when pH exceeds 6.0 or when divalent cations are introduced. Published data for terminal sterilisation kinetics of ephedrine HCl in multi-species veterinary parenterals is limited; therefore loading patterns and F₀ distribution are validated in the target container closure system per 21 CFR 211.166.

Powdered oral delivery of ephedrine veterinary grade API is limited to low-dose top-dressing where a single-step geometric dilution can be validated. The API is first levigated with a small portion of lactose monohydrate at 1:10, then tumble-mixed in a low-shear blender with dextrose or lactose to final concentration 0.1–0.5% w/w; colloidal silicon dioxide 0.2–0.5% w/w is included as a glidant. Finished powder loss on drying is held NMT 0.5% w/w for lactose-based systems, and blend uniformity is required at RSD ≤5.0%. Packaging in aluminum foil-lined HDPE jars with desiccant prevents moisture uptake above 60% RH; anticaking agents are used if storage temperature cycling produces caking. This format is generally unsuitable for high-dose delivery because powder density differences between API and carrier exaggerate segregation during transport and animal feeding.

When Ephedrine Sulfate Is Layered onto Granule Carriers for Oral Veterinary Dosing

When ephedrine sulfate is layered onto inert spheres, fluid-bed process controls become the primary determinant of dose uniformity and release. Microcrystalline cellulose spheres of 250–355 µm are charged to a Wurster insert; the API is dissolved or suspended with hydroxypropyl methylcellulose 2–4% w/w as binder and sprayed at 8–15 g/min/kg, inlet air 50–65°C, product temperature 30–40°C, and atomization air 1.5–2.5 bar. Drying continues to loss on drying NMT 1.5% w/w; the granule fraction is then sieved through 16–30 mesh, with bulk density controlled to 0.45–0.65 g/mL. High-shear granulation using an impeller at 200–400 rpm and chopper at 1500–3000 rpm is an alternative, but wet massing beyond 2–5 minutes commonly produces oversized granules and API migration to the periphery during tray drying. The finished veterinary granules are filled into foil-lined HDPE containers; desiccant is included because residual moisture above 2.0% w/w increases particle agglomeration and slows release. Content uniformity is measured per USP <905> and loss on drying by USP <731>; if dissolution is required for modified-release granules, USP <711> is applied with the species-specific fill medium specified in the marketing authorization.

For in-feed dry premix manufacture, the controlling variable is physical segregation rather than chemical degradation because ephedrine sulfate is dispersed at 0.1–2.0% w/w in a low-density organic carrier. Rice hulls, ground corn cobs, or calcium carbonate are mixed in a ribbon mixer with vegetable oil 0.5–1.0% w/w to reduce electrostatic adherence and improve API deposition on carrier surfaces. Geometric dilution is followed by a final blend time of 10–15 minutes, with mixer fill volume at 60–80% of rated capacity; extension beyond 30 minutes has been associated with increased fines and re-segregation on production-scale ribbon mixers. Assay sampling with a thief at 10 points must show RSD ≤5.0% under 21 CFR 211.110; cleaning validation for carryover is performed by swab and rinse sampling, although published residue limits for ephedrine premix are limited and require site-specific toxicological justification. Final moisture for organic carriers is held at ≤10% w/w to prevent mold growth during outdoor storage; ephedrine sulfate is generally selected over the hydrochloride salt where feed storage above 60% RH is unavoidable because the hydrochloride salt has greater hygroscopicity. Multi-wall paper bags with polyethylene liners are used, and inventory is rotated to avoid prolonged storage beyond the stability commitment under VICH GL3.

Solution Stability and Preservative Compatibility Limits in Multi-Dose Veterinary Packaging

Multi-dose oral solutions containing ephedrine hydrochloride are buffered to 4.0–5.0, because higher pH values ionize benzoate preservatives and reduce physical stability of the amine salt. Vehicle composition includes purified water, sorbitol or glycerin 10–30% w/w for palatability, sodium benzoate 0.1–0.2% w/v, potassium sorbate 0.05–0.1% w/v, and disodium edetate 0.01–0.05% w/v where trace-metal-catalyzed oxidation is observed. Nitrogen sparging during compounding and headspace oxygen below 2.0% v/v reduce oxidative degradation; amber PET or Type III glass containers are selected on the basis of photostability data generated under VICH GL3. In-use stability is validated for 28 days at 25°C and 60% RH, and microbial limits are assessed per USP <61> and USP <62> with specified organisms absent. Aldehyde-based flavoring agents are incompatible because ephedrine can form Schiff base condensation products; oxidizing agents and strong alkali are also excluded. If the solution is diluted in drinking water, the final dilution pH and hardness must be mapped because calcium and magnesium carbonates can raise pH above 5.5 and reduce preservative efficacy.